* The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at I...
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is p...
- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease tr...
* The first and only lipolytic injectable for large area – CBL-514's last Phase2b study has been ...
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that ...
NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to an...
* CBL-514 is the first product to treat cellulite at the raised areas. * Currently, there is no ...
* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track desig...
- CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track d...
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that ...
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that ...
NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that t...
CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants...
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has cl...
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of p...
TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical co...
- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of pain...
* CBL-514 is the only non-invasive product that can improve 1-level of cellulite severity two wee...
- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected...
